Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 21, Issue 6, 2009, Pages 258-263

  Feldman, Dmitriy N ^a   Wong, S Chiu ^a   Bergman, Geoffrey ^a   Minutello, Robert M ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HIRULOG; PACLITAXEL; RAPAMYCIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; DRUG EFFICACY; DRUG ELUTING STENT; EMERGENCY SURGERY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; RETROSPECTIVE STUDY; STROKE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 69249089700     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92. (Pubitemid 28321319)
2. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
3. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
4. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-959. (Pubitemid 33131801)
5. Shammas NW. Bivalirudin: Pharmacology and clinical applications. Cardiovasc Drug Rev 2005;23:345-360.
6. Lincoff AM, Bittl JA, Kleiman NS, et al; REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-1096.
7. Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863. (Pubitemid 37430344)
8. Ebrahimi R, Lincoff AM, Bittl JA, et al. Bivalirudin vs. heparin in percutaneous coronary intervention: A pooled analysis. J Cardiovasc Pharmacol Therapeut 2005;10:209-216. (Pubitemid 43003331)
9. Lincoff AM, Kleiman NS, Kereiakes DJ, et al; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703. (Pubitemid 39062523)
10. Exaire JE, Butman SM, Ebrahimi R, et al. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 2006;152:157-163. (Pubitemid 43974719)
11. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. Am Heart J 2004;148:764-775.
12. Stone GW, McLaurin BT, Cox DA, et al; for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216.
13. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-919.
14. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: One-year results from the ACUITY trial. JAMA 2007;298:2497-2506. (Pubitemid 350223536)
15. Sesso HD, Paffenbarger RS, Lee IM. Comparison of national death index and world wide Web death searches. Am J Epidemiol 2000;152:107-111.
16. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 2007;100:1364-1369. (Pubitemid 47576015)
17. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY trial. J Am Coll Cardiol 2007;49:1362-1368. (Pubitemid 46476844)
18. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-697. (Pubitemid 351221218)